论文部分内容阅读
高同型半胱氨酸血症(hyperhomocysteinemia,hHcy)是心血管病和终末期肾病发展的重要的独立危险因素。虽然降低同型半胱氨酸水平的多种方法已经用于实验研究和临床试验中,但是尚无有效的治疗可用于完全预防同型半胱氨酸诱导的靶器官损害。因此,识别致病途径中的关键分子可为hHcy相关损伤提供除了降低血浆同型半胱氨酸水平以外的新治疗策
Hyperhomocysteinemia (hHcy) is an important independent risk factor for the development of cardiovascular disease and end-stage renal disease. Although various methods of lowering homocysteine levels have been used in experimental studies and clinical trials, no effective treatment is available for complete prevention of homocysteine-induced target organ damage. Thus, identifying key molecules in pathogenic pathways may provide hHcy-related injuries with new therapeutic options in addition to reducing plasma homocysteine levels